These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma. Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390 [TBL] [Abstract][Full Text] [Related]
3. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. Damon LE; Johnson JL; Niedzwiecki D; Cheson BD; Hurd DD; Bartlett NL; Lacasce AS; Blum KA; Byrd JC; Kelly M; Stock W; Linker CA; Canellos GP J Clin Oncol; 2009 Dec; 27(36):6101-8. PubMed ID: 19917845 [TBL] [Abstract][Full Text] [Related]
4. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Hermine O; Hoster E; Walewski J; Bosly A; Stilgenbauer S; Thieblemont C; Szymczyk M; Bouabdallah R; Kneba M; Hallek M; Salles G; Feugier P; Ribrag V; Birkmann J; Forstpointner R; Haioun C; Hänel M; Casasnovas RO; Finke J; Peter N; Bouabdallah K; Sebban C; Fischer T; Dührsen U; Metzner B; Maschmeyer G; Kanz L; Schmidt C; Delarue R; Brousse N; Klapper W; Macintyre E; Delfau-Larue MH; Pott C; Hiddemann W; Unterhalt M; Dreyling M; Lancet; 2016 Aug; 388(10044):565-75. PubMed ID: 27313086 [TBL] [Abstract][Full Text] [Related]
5. Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma. Tam CS; Khouri IF Leuk Lymphoma; 2009 Aug; 50(8):1239-48. PubMed ID: 19562639 [TBL] [Abstract][Full Text] [Related]
6. R-CHOP or R-HyperCVAD with or without autologous stem cell transplantation for older patients with mantle cell lymphoma. Frosch Z; Luskin MR; Landsburg DJ; Schuster SJ; Svoboda J; Loren AW; Porter DL; Stadtmauer EA; Nasta SD Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):92-7. PubMed ID: 25174772 [TBL] [Abstract][Full Text] [Related]
7. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience. Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847 [TBL] [Abstract][Full Text] [Related]
8. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma. Jacobsen E; Freedman A Curr Opin Oncol; 2004 Mar; 16(2):106-13. PubMed ID: 15075900 [TBL] [Abstract][Full Text] [Related]
9. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386 [TBL] [Abstract][Full Text] [Related]
10. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients. Dreger P; Martin S; Kuse R; Sonnen R; Glass B; Kröger N; Parwaresch R; Kneba M; Schmitz N; Haas R Hematol J; 2000; 1(2):87-94. PubMed ID: 11920175 [TBL] [Abstract][Full Text] [Related]
11. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management. Vose JM Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102 [TBL] [Abstract][Full Text] [Related]
12. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial. Doorduijn JK; Zijlstra JM; Lugtenburg PJ; Kersten MJ; Böhmer LH; Minnema MC; MacKenzie MA; van Marwijk Kooij R; de Jongh E; Snijders TJF; de Weerdt O; van Gelder M; Hoogendoorn M; Leys RBL; Kibbelaar RE; de Jong D; Chitu DA; Van't Veer MB; Kluin-Nelemans HC Br J Haematol; 2020 Aug; 190(3):385-393. PubMed ID: 32150297 [TBL] [Abstract][Full Text] [Related]
14. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Dreyling M; Lenz G; Hoster E; Van Hoof A; Gisselbrecht C; Schmits R; Metzner B; Truemper L; Reiser M; Steinhauer H; Boiron JM; Boogaerts MA; Aldaoud A; Silingardi V; Kluin-Nelemans HC; Hasford J; Parwaresch R; Unterhalt M; Hiddemann W Blood; 2005 Apr; 105(7):2677-84. PubMed ID: 15591112 [TBL] [Abstract][Full Text] [Related]
15. Autologous stem cell transplantation in patients with mantle cell lymphoma. Oinonen R; Jantunen E; Itälä M; Lehtinen T; Kuittinen O; Franssila K; Wiklund T; Elonen E Leuk Lymphoma; 2002 Jun; 43(6):1229-37. PubMed ID: 12152990 [TBL] [Abstract][Full Text] [Related]
16. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Delarue R; Haioun C; Ribrag V; Brice P; Delmer A; Tilly H; Salles G; Van Hoof A; Casasnovas O; Brousse N; Lefrere F; Hermine O; Blood; 2013 Jan; 121(1):48-53. PubMed ID: 22718839 [TBL] [Abstract][Full Text] [Related]
17. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E; Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102 [TBL] [Abstract][Full Text] [Related]
18. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Geisler CH; Kolstad A; Laurell A; Jerkeman M; Räty R; Andersen NS; Pedersen LB; Eriksson M; Nordström M; Kimby E; Bentzen H; Kuittinen O; Lauritzsen GF; Nilsson-Ehle H; Ralfkiaer E; Ehinger M; Sundström C; Delabie J; Karjalainen-Lindsberg ML; Brown P; Elonen E; Br J Haematol; 2012 Aug; 158(3):355-62. PubMed ID: 22640180 [TBL] [Abstract][Full Text] [Related]
19. Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. Intragumtornchai T; Bunworasate U; Nakorn TN; Rojnuckarin P Leuk Lymphoma; 2006 Jul; 47(7):1306-14. PubMed ID: 16923561 [TBL] [Abstract][Full Text] [Related]
20. Autologous transplantation and management of younger patients with mantle cell lymphoma. Geisler CH Best Pract Res Clin Haematol; 2012 Jun; 25(2):211-20. PubMed ID: 22687457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]